Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,059 stopped studies mapped to Carcinoma of Unknown Primary and descendants · 91% state a reason
Over the 2,059 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05371860 | Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic Complete… | Phase 2 | withdrawn | May 12, 2022 | Armando Giuliano | PI voluntarily closed the study. Will be reopened as a national cooperative group trial. | Other (stated, no rule matched) |
| NCT02831933 | Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung…(ENSIGN) | Phase 2 | terminated | Jul 13, 2016 | Eric Bernicker, MD | Lack of funding | Funding |
| NCT04106167 | Long-term, Non-interventional, Observational Study Following Treatment With Fate… | — | terminated | Sep 26, 2019 | Fate Therapeutics | This study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT04193293 | A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer | Phase 1 / Phase 2 | terminated | Dec 10, 2019 | SecuraBio | The study was terminated due to low enrollment. | Enrollment / accrual |
| NCT05359692 | INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or… | Phase 2 | withdrawn | May 4, 2022 | Incyte Biosciences International Sàrl | Business decision; no safety concerns | Safety / toxicity |
| NCT01093183 | Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated… | Phase 1 / Phase 2 | terminated | Mar 25, 2010 | University of Nebraska | study sponsors withdrew support for the study drug. | Other (stated, no rule matched) |
| NCT01755650 | Phase 0 of 18F FPM Using PET/CT in Patients With a Variety of Malignancies | Early Phase 1 | terminated | Dec 24, 2012 | Peter MacCallum Cancer Centre, Australia | 6 patients were recuited. Due to inability of the tracer to detect regions of interest… | Other (stated, no rule matched) |
| NCT04834349 | Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of… | Phase 2 | withdrawn | Apr 8, 2021 | M.D. Anderson Cancer Center | No participants were enrolled | Enrollment / accrual |
| NCT05535023 | Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous… | Phase 2 | withdrawn | Sep 10, 2022 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT03623984 | Molecular-Guided Surgery for Pancreatic and GI Neuroendocrine Cancers | Early Phase 1 | withdrawn | Aug 9, 2018 | University of Alabama at Birmingham | no partipants | Other (stated, no rule matched) |
| NCT03912818 | Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant… | Phase 2 | terminated | Apr 11, 2019 | Stanford University | Difficulty with enrollment | Enrollment / accrual |
| NCT02524275 | Docetaxel and Capecitabine With Recurrent or Metastatic Squamous Cell Carcinoma of the… | Phase 2 | terminated | Aug 14, 2015 | University of Nebraska | low enrollment | Enrollment / accrual |
| NCT04441099 | NBE-002 in Patients With Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Jun 22, 2020 | NBE-Therapeutics AG | End of Program | Other (stated, no rule matched) |
| NCT05176288 | Avelumab, Palbociclib and Axitinib in Advanced RCC(APART) | Phase 2 | withdrawn | Jan 4, 2022 | Bradley A. McGregor, MD | The overall protocol will be changed in a new amendment, which will be resubmitted under the new… | Other (stated, no rule matched) |
| NCT02112552 | Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating… | Phase 2 | terminated | Apr 14, 2014 | Albert Einstein College of Medicine | Low accrual. Study formally terminated by PI on 12/1/2017 | Enrollment / accrual |
| NCT03963414 | A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC | Phase 1 | terminated | May 24, 2019 | University of Nebraska | low accrual | Enrollment / accrual |
| NCT04720664 | Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer(OASIS) | Phase 2 | terminated | Jan 22, 2021 | Georgetown University | Lack of efficacy | Efficacy / futility |
| NCT04271254 | PET/MR Characterization of Renal Cell Carcinomas | N/A | terminated | Feb 17, 2020 | UNC Lineberger Comprehensive Cancer Center | Funding insufficiency. | Funding |
| NCT05027867 | KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer | Phase 2 | terminated | Aug 30, 2021 | Kartos Therapeutics, Inc. | Unanticipated and extremely high screen failure rate. There was no evidence of safety concerns in… | Safety / toxicity |
| NCT04185311 | Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating… | Phase 1 | terminated | Dec 4, 2019 | Jonsson Comprehensive Cancer Center | enrollment | Enrollment / accrual |
| NCT01712815 | PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer | N/A | terminated | Oct 24, 2012 | University of Southern California | Insufficient accrual | Enrollment / accrual |
| NCT04750239 | Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell… | Phase 1 / Phase 2 | terminated | Feb 11, 2021 | Y-mAbs Therapeutics | Study terminated due to business priorities | Sponsor / business decision |
| NCT05729139 | Cemiplimab/Peg-Interferon-α in Advanced CSCC | Phase 1 | withdrawn | Feb 15, 2023 | Baptist Health South Florida | PI is leaving institution prior to study opening for accrual. | Enrollment / accrual |
| NCT04644315 | A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in…(ALpha-T) | Phase 2 | terminated | Nov 25, 2020 | Hoffmann-La Roche | The data from this study is no longer needed. | Other (stated, no rule matched) |
| NCT00707655 | Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible… | Phase 1 / Phase 2 | terminated | Jul 1, 2008 | Genmab | The decision is based on company re-evaluation of indications to be pursued within SCCHN | Sponsor / business decision |
| NCT03024996 | A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma…(IMmotion010) | Phase 3 | terminated | Jan 19, 2017 | Hoffmann-La Roche | The sponsor decided to terminate this study before the protocol-defined end-of-study, as permitted… | Sponsor / business decision |
| NCT04639245 | Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous… | Phase 1 / Phase 2 | terminated | Nov 20, 2020 | Fred Hutchinson Cancer Center | Terminated due to slow accrual. | Enrollment / accrual |
| NCT04922112 | Sleep Apnea in Head and Neck Cancer Patients at the University of Colorado(OSA-HN) | N/A | withdrawn | Jun 10, 2021 | University of Colorado, Denver | Unable to find participants, no enrollment | Enrollment / accrual |
| NCT02059265 | Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube,… | Phase 2 | terminated | Feb 11, 2014 | National Cancer Institute (NCI) | Interim monitoring | Other (stated, no rule matched) |
| NCT03576131 | GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors | Phase 1 / Phase 2 | terminated | Jul 3, 2018 | Genmab | Sponsor decision | Sponsor / business decision |
| NCT04424641 | A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid… | Phase 1 / Phase 2 | terminated | Jun 11, 2020 | Genmab | Study was terminated due to MTD was reached | Other (stated, no rule matched) |
| NCT04688749 | Use of Electrical Impedance Spectroscopy (EIS) for Early Diagnosis of Skin Damage(DermaSense) | — | terminated | Dec 30, 2020 | Aristotle University Of Thessaloniki | Due to COVID-19 | COVID-19 / pandemic |
| NCT05809895 | Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With…(AdvanTIG-211) | Phase 2 | withdrawn | Apr 12, 2023 | Novartis Pharmaceuticals | Business decision, not driven by safety concerns; no new safety signals have been observed in the… | Safety / toxicity |
| NCT05584332 | A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV… | Phase 3 | terminated | Oct 18, 2022 | Shanghai Bovax Biotechnology Co., Ltd. | Strategic adjustment | Sponsor / business decision |
| NCT02592707 | Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs | Phase 1 / Phase 2 | terminated | Oct 30, 2015 | Ipsen | Terminated (Due to small number of ongoing patients. Patients ongoing at time of termination could… | Other (stated, no rule matched) |
| NCT03740100 | Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of…(HNSCC) | Phase 2 | terminated | Nov 14, 2018 | M.D. Anderson Cancer Center | The trial was closed because the sponsor became insolvent. | Other (stated, no rule matched) |
| NCT05109052 | Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating… | Phase 1 / Phase 2 | withdrawn | Nov 5, 2021 | University of Rochester | no accrual of eligible participants | Enrollment / accrual |
| NCT03970616 | A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced…(DEDUCTIVE) | Phase 1 / Phase 2 | terminated | May 31, 2019 | AVEO Pharmaceuticals, Inc. | The study was terminated due to regulatory approval of newer therapeutic options and slower than… | Enrollment / accrual |
| NCT03722498 | Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE | Phase 2 | withdrawn | Oct 29, 2018 | Sun Yat-sen University | No patients join | Other (stated, no rule matched) |
| NCT04781374 | Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer | Phase 2 | withdrawn | Mar 4, 2021 | Beth Israel Deaconess Medical Center | Withdrawal of funding | Funding |
| NCT05255666 | Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer… | Phase 2 | withdrawn | Feb 24, 2022 | Washington University School of Medicine | No drug | Other (stated, no rule matched) |
| NCT02530437 | Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With… | Phase 1 / Phase 2 | terminated | Aug 21, 2015 | M.D. Anderson Cancer Center | The sponsor sold the drug TALADEGIB to another company during the trial and thereafter no drug was… | Sponsor / business decision |
| NCT03591965 | Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular… | Phase 2 | terminated | Jul 19, 2018 | Antengene Therapeutics Limited | Based on the adjustment of clinical research and development strategy，sponsor decided to terminate… | Sponsor / business decision |
| NCT00303628 | Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III… | Phase 3 | terminated | Mar 17, 2006 | ECOG-ACRIN Cancer Research Group | The study was terminated before reaching its accrual goal due to slow accrual. | Enrollment / accrual |
| NCT03986593 | Cryoablation of Bone Metastases From Endocrine Tumors | N/A | terminated | Jun 14, 2019 | Instituto do Cancer do Estado de São Paulo | The study achieved n=17 participants (56.6% of the initial proposition) with a mean = 18 months… | Other (stated, no rule matched) |
| NCT02031536 | Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver… | Phase 2 | terminated | Jan 9, 2014 | ECOG-ACRIN Cancer Research Group | Slow accrual | Enrollment / accrual |
| NCT01824823 | Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous… | Phase 2 | terminated | Apr 5, 2013 | ECOG-ACRIN Cancer Research Group | Slow accrual | Enrollment / accrual |
| NCT04252612 | Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A… | Early Phase 1 | withdrawn | Feb 5, 2020 | H. Lee Moffitt Cancer Center and Research Institute | Poor accrual | Enrollment / accrual |
| NCT02067741 | CR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast Cancer | Phase 2 | terminated | Feb 20, 2014 | Swiss Cancer Institute | The SAKK board decided to prematurely end the life-long follow-up of the trial SAKK 21/12, as 90%… | Other (stated, no rule matched) |
| NCT02488629 | Study of SCB01A in Patient With Head and Neck Cancer | Phase 2 | terminated | Jul 2, 2015 | SynCore Biotechnology Co., Ltd. | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Sep 22, 2023source: clinicaltrials